| Data | Ora | Fonte | Titolo | Simbolo | Compagnia |
| 10/03/2025 | 21:43 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 08/03/2025 | 00:15 | Edgar (US Regulatory) | Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 06/03/2025 | 22:06 | Edgar (US Regulatory) | Form 144 - Report of proposed sale of securities | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 28/02/2025 | 22:11 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 28/02/2025 | 02:22 | Edgar (US Regulatory) | Form 3 - Initial statement of beneficial ownership of securities | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 26/02/2025 | 08:49 | GlobeNewswire Inc. | BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 24/02/2025 | 22:09 | GlobeNewswire Inc. | BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 20/02/2025 | 22:00 | Edgar (US Regulatory) | Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 20/02/2025 | 13:30 | GlobeNewswire Inc. | BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 13/02/2025 | 22:01 | GlobeNewswire Inc. | BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025 | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 11/02/2025 | 15:21 | GlobeNewswire Inc. | BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 13/01/2025 | 17:00 | GlobeNewswire Inc. | BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 08/01/2025 | 13:30 | GlobeNewswire Inc. | BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 13/12/2024 | 13:18 | GlobeNewswire Inc. | Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 23/11/2024 | 01:11 | GlobeNewswire Inc. | Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 18/11/2024 | 17:15 | GlobeNewswire Inc. | Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 18/11/2024 | 11:30 | GlobeNewswire Inc. | BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 12/11/2024 | 13:30 | GlobeNewswire Inc. | BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 05/11/2024 | 13:30 | GlobeNewswire Inc. | BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 24/10/2024 | 13:30 | GlobeNewswire Inc. | BridgeBio Shares Positive Data from High Dose Cohort of Phase 1/2 CANaspire Study of Gene Therapy BBP-812 for Canavan Disease at ESGCT 2024 | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 23/10/2024 | 00:06 | Edgar (US Regulatory) | Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 03/10/2024 | 13:30 | GlobeNewswire Inc. | BridgeBio to Present Outcomes Data Through 42 Months from the Open-Label Extension of ATTRibute-CM, the Phase 3 Study of Acoramidis for Treatment of ATTR-CM, at 2024 AHA Scientific Sessions | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 30/09/2024 | 13:30 | GlobeNewswire Inc. | BridgeBio Completes Enrollment of FORTIFY, Phase 3 Registrational Study of BBP-418 in Limb-girdle Muscular Dystrophy Type 2I/R9 (LGMD2I/R9) | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 28/09/2024 | 00:00 | GlobeNewswire Inc. | BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 18/09/2024 | 00:41 | Edgar (US Regulatory) | Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 17/09/2024 | 13:30 | GlobeNewswire Inc. | BridgeBio Announces Infigratinib Is the First Ever Investigational Therapeutic Option for Achondroplasia to Be Awarded Breakthrough Therapy Designation by the FDA | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 10/09/2024 | 22:45 | GlobeNewswire Inc. | BridgeBio Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for BBP-812 Canavan Disease Gene Therapy Program | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 10/09/2024 | 22:45 | GlobeNewswire Inc. | BridgeBio Pharma Reports Topline Results from Phase 1/2 Trial of Investigational Gene Therapy for Congenital Adrenal Hyperplasia (CAH) | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 06/09/2024 | 13:30 | GlobeNewswire Inc. | BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | NASDAQ:BBIO | BridgeBio Pharma Inc |
| 30/08/2024 | 16:50 | GlobeNewswire Inc. | BridgeBio Shares Data on Serum TTR Increase When Switching Participants from Placebo and Tafamidis to Acoramidis in ATTRibute-CM and its Open-Label Extension | NASDAQ:BBIO | BridgeBio Pharma Inc |
